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albicans strains adhere better to epithelial cells of the oral cavity
or the esophagus, but it is accepted that esophageal candidiasis
represents a form of invasive candidiasis which requires higher
dosages of antifungal drugs compared to OPC [11]. In this
patient, replacement of a fluconazole-resistant C. albicans strain
by a genetically different fluconazole-sensitive strain was
observed; this finally caused further recurrences of OPC, which
responded well to intermittent therapy with itraconazole solu-
tion. However, it is unclear whether the disappearance of the
resistant genotype is due to the temporary increase of the CD4
cell count or because of therapy with itraconazole despite high-
level resistance to azoles in vitro.
It may be concluded that serial DNA typing of C. albicans
strains, together with antifungal susceptibility testing, may help
us to monitor the susceptibility of clinical isolates to azole
therapy.
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Many Legionella species are found in the natural environment
and one of them, Legionella pneumophila, is responsible for more
than 90% of cases of Legionnaires’ disease [1]. Outbreaks of
community-acquired and nosocomial L. pneumophila infections
have been described [2,3].
The laboratory detection of the Legionella infection remains
difficult. The serological diagnosis, although fairly specific, has
a sensitivity in the 70–80% range depending on the following:
(i) the single antibody test used ,and (ii) the detection of anti-
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body to Legionella species or serogroups other than L. pneu-
mophila serogroup 1 [4]. The results are also highly influenced
by the kind of antigen (formolized or heated) used for the
diagnosis of seroconversion. In addition, serological diagnosis
can be difficult since the rise in antibody titres can be delayed.
The sensitivity of the direct fluorescence assay for the antigen
detection remains highly variable, from 30 to 80% [5]. The
detection of the L. pneumophila serogroup 1 urinary antigen
with commercially available enzyme immunoassay (EIA) kits
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seems highly specific (100%) and fairly sensitive (percentages
vary from 63.76 to 66.66% in non-concentrated urine and from
86.66 to 88.88% in concentrated urine) [6]. However, the
urinary kits are expensive and the need to include control tests
increases their cost, particularly for small series.
The culture of the bacterium remains the standard and prob-
ably continues to be the most sensitive means of diagnosis when
it is performed early in the course of disease. However, the
isolation of L. pneumophila is time-consuming and needs special
culture media. Moreover, it has been reported that several L.
pneumophila strains grown in chick embryos, are not detectable
by culture on agar media [7].
DNA amplification is an interesting alternative method for
bacterial detection. Amplification of Legionella-specific DNA
sequences has been used to detect the bacterium in environ-
mental water samples [8,9]. Primers selected from the macro-
phage infectivity potentiator gene (mip) of L. pneumophila [10]
have also been used for detection in environmental water and,
more recently, in bronchoalveolar lavage fluid [11]. We
described the use of a commercial kit, which was designed to
detect the DNA of both the genus Legionella and the species L.
pneumophila in environmental water samples, for the detection
of L. pneumophila in clinical samples [12]. More recently, Mur-
doch et al. [13] described the detection of Legionella DNA in
urine and serum samples, from patients with pneumonia, with
a polymerase chain reaction (PCR) assay by using two 20-
mer primers (L5SL9 and L5SR93), which amplified a 104-bp
segment of the coding region of the 5S rRNA gene.
The aim of the present study was the detection of L. pneu-
mophila DNA with a PCR and microplate hybridization assay
in serum and urine samples from patients with legionellosis.
Serum samples from 41 patients with proven legionellosis
and from 10 patients with pneumonia due to other organisms
(controls) were studied. The legionellosis was proven either
by positive L. pneumophila culture (nine patients), or by L.
pneumophila antibody detection: if we had only one serum the
antibody titre was more than 256, and if we had two contiguous
samples (second sample taken 15 days later) from the same
patient, the second one had a rise in antibody titre of more than
four-fold.
Thirty samples of urine from the same set of patients with
pneumonia (we had sera not accompanied by urine) were also
tested for the presence of L. pneumophila serogroup 1 antigen
with the Binax (Portland, ME, USA) enzyme immunoassay
and 20 samples that were found to be positive and 10 that were
found to be negative were included in the study.
Total DNA from the serum samples was extracted using a
DNA extraction reagent containing the Chelex anion-ex-
change resin (Perkin Elmer, NJ, USA), as described previously
[14]. Total DNA from the urine samples was extracted using
the IsoQuick reagent (ORCA Research Inc., Bothell, WA,
USA) [15–17].
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A PCR assay with primers Leg1 (5?-GTCATGAGGAA-
TCTCGCG-3?) and Leg2 (5?-CTGGCTTCTTCCAGC-
TTCA-3?) that specifically amplify a 700-base pair fragment of
L. pneumophila was used as described previously [18], in order
to detect the DNA of this bacterium in serum and urine samples
from patients with pneumonia. The amplification products
were at first visualized after agarose-gel electrophoresis and
ethidium bromide staining.
To enhance the sensitivity and specificity of the PCR assay,
amplified products were detected after hybridization in Hybrid-
owell microtitre plates (Argene Biosoft, Varilhes, France),
according to the manufacturer’s instructions. Briefly, 2 ml of
amplified product was directly coated on a microtitre plate, and
incubated for 2 h at 37 °C. After hybridization with hybrid-
ization solution containing 50 ng/mL of the biotinylated oli-
gonucleotidic probe Leg3 (5?-GTCCGTTATGGGGTA-
TTGATCACC-3?) [18] for 30 min at 37 °C, hybrids were
detected by streptavidin-peroxydase conjugate. The chromo-
gen used was tetramethylbenzidine and the instrument used to
monitor the signal was a microwell plate reader. The cut-off
(CO) was calculated from the mean of the two values obtained
with the kit negative control according to the equations: OD
reading at 450 nm: CO = OD mean (negative control) 2 0.150
and OD reading at 450/650 nm: CO = OD average (negative
control) + 0.075.
The negative control OD of the kit must be 0.4 OD units.
The OD obtained with the amplification positive control must
be above the cut-off. If the controls are validated, the results
may be analyzed as follows: if the OD  CO + 10%; the ampli-
fication is positive, if the OD  CO  10%; the amplification
is negative and if the OD = CO 2 10%; the amplified product
must be retested.
Sequencing (ABI PRISM dye-terminator cycle sequencing)
of three of the amplification products was used to confirm the
specificity of the method.
Legionella pneumophila DNA was detected in 12 serum sam-
ples from the 41 patients with legionellosis (29%) and it was not
detected in serum samples from the 10 controls. The presence of
L. pneumophila DNA in the serum samples was not found to be
related to the presence of positive cultures from broncho-
alveolar aspirates or the serum antibody titres. In addition,
positive results were found both in seven of the 15 ‘early’ (2–4
days) and in five of the 26 ‘late’ (10–15 days) serum samples
after the onset of pneumonia. Legionella pneumophila DNA was
also detected in six urine samples from the 20 patients with
legionellosis and it was not detected in urine samples from the
10 controls. Positive results were found both in two of nine
‘early’ and in four of 11 ‘late’ urine samples after the onset of
pneumonia, as described in serum samples.
Our results are in accordance with those previously reported
by Murdoch et al. [13], which described the detection of
Legionella DNA by PCR in urine and serum samples from
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patients with pneumonia. These authors used primers that
amplified a segment of the 5S rRNA gene present in all
Legionella species followed by a restriction enzyme analysis to
confirm the specificity of the amplified PCR products. We
obtained in our study a relatively lower sensitivity in sera and
especially in urine samples although the samples tested were
obtained from patients with L. pneumophila serogroup 1 infec-
tion and the primers used were specific for the bacterium.
The detection of Legionella DNA in the serum and urine
samples remains a good alternative as diagnosis by the culture
of the bacterium is time-consuming and needs special culture
media and serological diagnosis is not very sensitive. Our results
suggest that the molecular methods we used were specific but
not very sensitive. In order to improve the sensitivity of our
methods we must try other DNA extraction methods and pri-
mers and probes from different sequence regions. Indeed, Mur-
doch et al. [13] obtained a better sensitivity by using another
amplification and hybridization target. The DNA con-
centration from urine could also play a role in the sensitivity of
the method, as described for urinary antigen detection by EIA
[6], however, the PCR before hybridization increases the DNA
concentration in the sample examined. Collection of urine
samples on consecutive days could increase the sensitivity of the
method, since excretion of DNA in urine can be intermittent as
described by Murdoch et al. [13]. Finally, the relatively low
frequency of the bacteremia associated with legionellosis, in
addition to the small amount of breakdown of nucleic acid
products after macrophage lysis, could explain the poor sen-
sitivity of DNA detection in the serum.
In conclusion, our results suggest that the detection of L.
pneumophila DNA by our method can assist the rapid diagnosis
of Legionella infection. Further investigations will be needed to
see if the sensitivity could be increased by testing multiple
specimens, by using a modification of the assay or other PCR
targets and assays. Whether positive results are due to Legionella
bacteremia or to breakdown products (nucleic acids) that are
present during the infection, also remains to be elucidated.
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